Role of tyrosine kinase inhibition with imatinib in an encapsulating peritoneal sclerosis rat model

Renal Failure

Volumn 35, Issue 4, 2013, Pages 531-537

  Velioglu, Arzu ^a   Tugtepe, Halil ^a   Asicioglu, Ebru ^a   Yilmaz, Neslihan ^a   Filinte, Deniz ^a   Arikan, Hakki ^a   Koc, Mehmet ^a   Tuglular, Serhan ^a   Kaya, Handan ^a   Ozener, Cetin ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Fibrosis; Imatinib; Inflammation; Peritoneal dialysis; TGF

Indexed keywords

CHLORHEXIDINE GLUCONATE; CREATININE; GLEVEC; GLUCOSE; IMATINIB; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSATE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIUM CELL; MICROSCOPY; NONHUMAN; PERITONEAL FIBROSIS; PRIORITY JOURNAL; RAT; TREATMENT DURATION; ULTRAFILTRATION;

ANIMALS; BENZAMIDES; CHLORHEXIDINE; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MALE; PERITONEAL FIBROSIS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84876378894     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.773915     Document Type: Article

References (24)

1. Balasubramaniam G, Brown EA, Davenport A, et al. The Pan-Thames EPS study: Treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2009;24(10): 3209-3215
2. Beyer C, Distler JH, Distler O. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss Med Wkly. 2010;140:w13050, doi:10.4414/ smw.2010.13050
3. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14): 1031-1037
4. Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004; 114(9):1308-1316
5. Distler JH, Distler O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: Towards molecular targeted therapies. Ann Rheum Dis. 2010;69(Suppl. 1):i48-i51
6. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009;60(1):219-224
7. Abdollahi A, Li M, Ping G, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005;201(6):925-935
8. Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J. 2005;19(1):1-11
9. Yoshiji H, Noguchi R, Kuriyama S, et al. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol. 2005;288(5):G907-G913
10. Hoff CM. Experimental animal models of encapsulating peritoneal sclerosis. Perit Dial Int. 2005;25(Suppl. 4):S57- S66
11. Io H, Hamada C, Ro Y, et al. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int. 2004;65:1927-1936
12. Di Paolo N, Nicolai GA, Garosi G. The peritoneum: From histological studies to mesothelial transplant through animal experimentation. Perit Dial Int. 2008;28(Suppl. 5):S5-S9
13. Yu MA, Shin KS, Kim JH, et al. HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium. J Am Soc Nephrol. 2009;20(3):567-581
14. Huang JW, Yen CJ, Wu HY, et al. Tamoxifen downregulates connective tissue growth factor to ameliorate peritoneal fibrosis. Blood Purif. 2011;31(4):252-258
15. Ertilav M, Hur E, Bozkurt D, et al. Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model. Nephrology (Carlton). 2011;16(6):552-557
16. Bozkurt D, Bicak S, Sipahi S, et al. The effects of colchicine on the progression and regression of encapsulating peritoneal sclerosis. Perit Dial Int. 2008;28(Suppl. 5):S53-S57
17. Duman S, Bozkurt D, Sipahi S, et al. Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model. Adv Perit Dial. 2008;24: 104-110
18. Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Thannickal VJ. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: Implications for treatment of fibrotic diseases. J Pharmacol Exp Ther. 2007;321(1):35-44
19. Strippoli R, Benedicto I, Perez Lozano/m L, et al. Inhibition of transforming growth factor-activated kinase 1 (TAK1) blocks and reverses epithelial to mesenchymal transition of mesothelial cells. PLoS One 2012;7(2):e31492
20. Tejde M, Hadimeri H, Siegert CE, et al. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int. 2009;29(6):647-655
21. Yung S, Chan TM. Mesothelial cells. Perit Dial Int. 2007;27 (Suppl. 2):S110- S115
22. Lai KN, Lam MF, Leung JC. Peritoneal function: The role of aquaporins. Perit Dial Int. 2003;23(Suppl. 2):S20-S25
23. Liakopoulos V, Zarogiannis S, Hatzoglou C, et al. Inhibition by mercuric chloride of aquaporin-1 in the parietal sheep peritoneum: An electrophysiologic study. Adv Perit Dial. 2006;22: 7-10
24. Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29(5):976-985